C12N 2760/18043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2760/18043 (Viral genome or elements thereof as genetic vector) appears on 8 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 8
- Published applications
- 17
- Assignees
- 15
- Inventors
- 31
- Latest grant
- 18 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 2 |
| 2018 | 1 | 1 |
| 2019 | 2 | 2 |
| 2020 | 1 | 3 |
| 2021 | 0 | 0 |
| 2022 | 2 | 1 |
| 2023 | 1 | 0 |
| 2024 | 0 | 2 |
| 2025 | 1 | 4 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Paramyxovirus vector18 Mar 2025US 12,252,700 B2ID Pharma Co., Ltd.
- Expression systems comprising nucleic acids encoding HIV-1 protease cleavage site polypeptides14 Nov 2023US 11,813,325 B2Her Majesty the Queen in right of Canada, as represented by the Minister of Health
- Modified PEDV spike protein11 Oct 2022US 11,464,852 B2
- Methods of inducing an immune response against HIV-1 utilizing nucleic acids encoding polypeptides containing HIV-1 protease cleavage sites19 Jul 2022US 11,389,527 B2Her Majesty the Queen in right of Canada, as represented by the Minister of Health
- Nanoparticles carrying immunogenic peptides targeting HIV-1 protease cleavage sites14 Apr 2020US 10,617,645 B2
- Recombinant rsv vaccine: methods of making and using the same9 Jul 2026US 2026/0193671 A1Blue Lake Biotechnology, Inc.
- Method for reprogramming human somatic cells into induced pluripotent stem cells14 May 2026US 2026/0132384 A1Exoneuglia Biotechnology (Suzhou) Co., Ltd.
- Methods for production of ipscs6 Nov 2025US 2025/0340836 A1New York Stem Cell Foundation, Inc.
- Viral vectors3 Jul 2025US 2025/0213674 A1City, University of London
- Recombinant live attenuated rsv vaccine strain and production method therefor24 Apr 2025US 2025/0127872 A1SK Bioscience Co., Ltd.
Most cited
By later US patents
- Methods of inducing an immune response against HIV by administering immunogenic peptides obtained from protease cleavage sites2US 10,285,942 B2Her Majesty the Queen in right of Canada, as represented by the Minister of Health · 2019
- Immunogenic composition1US 9,950,059 B2The United States of America as represented by the Secretary of Agriculture · 2018